Search Results

You are looking at 11 - 20 of 470 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Philip Sobash and Nagla Abdel Karim

Background: The use of adjuvant chemotherapy following the surgical resection of pulmonary typical or atypical carcinoids has been highly debated. Guidelines currently indicate potential chemotherapy treatment for Stage IIIA disease in typical or

Full access

Harold J. Burstein

present, the NCCN Guidelines for Breast Cancer enumerate no fewer than 12 adjuvant chemotherapy regimens, with another 6 for HER2-positive disease. Each of these has been studied in phase III trials and has historical data to support its use. Some of these

Full access

Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl

population-based study demonstrated superior disease-free survival with addition of whole abdominal RT (WART) to 3 cycles of adjuvant chemotherapy in patients with stage II OCCC or a select subgroup of patients with stage IC disease (ICo) characterized by

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk

-targeted therapies, such as trastuzumab. 3 – 5 However, outcomes for patients with HER2+ breast cancer treated outside of clinical trials are limited. 6 , 7 In small, node-negative, HER2+ tumors, the benefit of adding trastuzumab to adjuvant chemotherapy

Full access

Inga T. Lennes, Mara Bloom, Nie Bohlen, and Beverly Moy

cancer started chemotherapy more than 120 days after diagnosis, which is considered suboptimal care. 1 - 3 Similarly, data from the NCCN Oncology Outcomes Database showed a small proportion of patients with breast cancer who started adjuvant chemotherapy

Full access

Benjamin M. Parsons, Dipesh Uprety, Angela L. Smith, Andrew J. Borgert, and Leah L. Dietrich

No definite preferred standard of care exists for adjuvant chemotherapy (ACT) in patients with node-negative, HER2-positive breast cancers measuring <2 cm. 1 Prior to the advent of HER2-directed therapy, HER2 overexpression was a marker of poor

Full access

David Scott Miller, Gini Fleming, and Marcus E. Randall

2006 ; 24 : 36 – 44 . 2 Maggi R Lissoni A Spina F . Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial . Br J Cancer 2006 ; 95 : 266 – 271 . 3 Alvarez Secord A Havrilesky LJ

Full access

Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans, and Cary P. Gross

hormone therapy and 88.8% with adjuvant chemotherapy and endocrine therapy. Her oncologist considered Oncotype DX (ODX) testing to help chemotherapy decision-making. Given the current emphasis on value-based practice, is ODX cost-effective for someone like

Full access

David A. Kooby and Daniel G. Coit

advanced gastric cancer . Ann Surg 1992 ; 216 : 269 – 278 . 48 The Gastrointestinal Tumor Study Group . Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer . Cancer 1982 ; 49 : 1116 – 1122 . 49

Full access

Jashodeep Datta, Matthew T. McMillan, Eric K. Shang, Ronac Mamtani, Russell S. Lewis Jr, Rachel R. Kelz, Ursina Teitelbaum, John P. Plastaras, Jeffrey A. Drebin, Douglas L. Fraker, Giorgos C. Karakousis, and Robert E. Roses

guidelines, visit NCCN.org ). 11 The latter recommendation reflects findings from the CLASSIC trial; specifically, improved DFS and OS in patients receiving adjuvant chemotherapy (capecitabine/oxaliplatin) compared with those undergoing surgery alone. 11